These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 7677965)

  • 21. Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia.
    al-Khatti A; Umemura T; Clow J; Abels RI; Vance J; Papayannopoulou T; Stamatoyannopoulos G
    Trans Assoc Am Physicians; 1988; 101():54-61. PubMed ID: 2480020
    [No Abstract]   [Full Text] [Related]  

  • 22. Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience.
    Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
    Prog Clin Biol Res; 1989; 316B():281-93. PubMed ID: 2482498
    [No Abstract]   [Full Text] [Related]  

  • 23. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
    Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sickle cell anemia: targeting the role of fetal hemoglobin in therapy.
    Coleman E; Inusa B
    Clin Pediatr (Phila); 2007 Jun; 46(5):386-91. PubMed ID: 17556734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia.
    Embury SH; Dozy AM; Miller J; Davis JR; Kleman KM; Preisler H; Vichinsky E; Lande WN; Lubin BH; Kan YW; Mentzer WC
    N Engl J Med; 1982 Feb; 306(5):270-4. PubMed ID: 6172710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis.
    Letvin NL; Linch DC; Beardsley GP; McIntyre KW; Miller BA; Nathan DG
    J Clin Invest; 1985 Jun; 75(6):1999-2005. PubMed ID: 2409112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
    Dover GJ; Charache S; Boyer SH
    Trans Assoc Am Physicians; 1984; 97():140-5. PubMed ID: 6085527
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.
    Perrine SP; Olivieri NF; Faller DV; Vichinsky EP; Dover GJ; Ginder GD
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):67-71. PubMed ID: 7508690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea.
    Letvin NL; Linch DC; Beardsley GP; McIntyre KW; Nathan DG
    N Engl J Med; 1984 Apr; 310(14):869-73. PubMed ID: 6199670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.
    de Franceschi L; Rouyer-Fessard P; Alper SL; Jouault H; Brugnara C; Beuzard Y
    Blood; 1996 Feb; 87(3):1188-95. PubMed ID: 8562946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Terrin ML; Moore RD; Dover GJ; Barton FB; Eckert SV; McMahon RP; Bonds DR
    N Engl J Med; 1995 May; 332(20):1317-22. PubMed ID: 7715639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of HBF production by erythropoietin.
    Stamatoyannopoulos G; Umemura T; al-Khatti A; Spadaccino E; Abels RI; Fritsch EF; Papayannopoulou T
    Prog Clin Biol Res; 1989; 316B():269-80. PubMed ID: 2482497
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.